International Stem Cell Corporation (OTCBB:ISCO) www.internationalstemcell.com,
a California-based biotechnology company focused on therapeutic and
research products, announced today the selection of the Richards
Partners as agency of record for its wholly owned subsidiary Lifeline
Skin Care, Inc. ("Lifeline"). Lifeline offers luxury anti-aging skin
care products based on its proprietary stem cell technology. Based in
Dallas, the Richards Partners is the nation's largest independent
branding agency.
Lifeline's skin care products were developed by a team of ISCO research
scientists in collaboration with world-renowned cosmetic experts, and
offer a comprehensive approach to skin care using patent pending
moisture serums for day and night use. Made with human parthenogenetic
stem cell extracts, the serums deliver anti-aging benefits, resulting in
healthier and younger-looking skin. These products were launched in
November 2010 and are available for purchase through the www.lifelineskincare.com
website and selected luxury spas across the United States.
Adding Richards Partners to the Lifeline Skin CareTM team is
part of Lifeline's plan to build on its initial successful product
launch last year, and the Web based sales that have followed, by
initiating a series of new marketing campaigns to further develop the
Lifeline Skin CareTM brand identity. These new marketing
initiatives include traditional print and news media campaigns, as well
as a new digital strategy focused on Internet and social media. "We are
looking forward to working closely with the Richards Partners and
leveraging their expertise in these areas to enhance the profile of
Lifeline Skin CareTM and its revolutionary new skin care
products," says Lifeline CEO Ruslan Semechkin, PhD. "Building a globally
recognizable brand is a long-term process and this is an important step
towards creating Lifeline's name. We believe this is a good time to
begin these campaigns and continue our sales momentum resulting from our
successful initial launch," Dr. Semechkin continued.
As previously announced the Mauldin Group, Lifeline's marketing partner,
will be managing the day to day relationship with the Richards Partners
and planning additional direct marketing initiatives similar to the
successful initial launch in 2010. Tiffani Mauldin-Frederick, marketing
partner of Lifeline Skin CareTM, says, "We're excited about
working together with Richards Partners. We believe the collaboration
will provide additional momentum and increase brand recognition for
Lifeline Skin CareTM and help educate the public about the
revolutionary science behind these products."
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on the therapeutic applications of human parthenogenetic
stem cells and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology, parthenogenesis,
results in creation of pluripotent human stem cells from unfertilized
oocytes (eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells with minimal immune rejection after transplantation
into hundreds of millions of individuals of differing sexes, ages and
racial groups. This offers the potential to create the first true stem
cell bank, UniStemCell™, while avoiding the ethical issue of using
fertilized eggs. ISCO also produces and markets specialized cells and
growth media for therapeutic research worldwide through its subsidiary
Lifeline Cell Technology and cell-based skin care products through its
subsidiary Lifeline Skin Care. More information is available at ISCO's
website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated developments, product introduction
plans and related support, the potential benefits of products, and other
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and ability to
obtain future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update forward-looking statements.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care,
anti-aging
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 1-760-940-6383 kaldrich@intlstemcell.com or Lifeline
Skin Care, Inc. Ruslan Semechkin, PhD, President & CEO Vice
President, ISCO ras@intlstemcell.com |